Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial

Authors

  • Laurence Klotz Sunnybrook Health Sciences Centre, University of Toronto
  • Abdenour Nabid Dept Radiation Oncology, Centre Hospitalier de Universitaire de Sherbrooke
  • Celestia Higano University of Washington Seattle Cancer Care Alliance, Seattle, WA, USA;
  • Chris Ryan Department of Medicine, Oregon Health Sciences University, Portland, OR, USA;
  • marlene Kebabdjian Division of Urology, Sunnybrook Health Sciences Centre
  • Joseph Chin Division of Urology, London Health Sciences Centre, London, Ontario, Canada

DOI:

https://doi.org/10.5489/cuaj.2332

Keywords:

prostate cancer, intermittent androgen deprivation, 5 ARI,

Abstract

Introduction: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy.

Methods: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was <1.0 ng/mL. ADT was resumed when PSA increased to ≥5.0 ng/mL. End points included time off treatment, PSA nadir after 9 months of ADT, serum testosterone and dihydrotestosterone levels, and time to castrate-resistant prostate cancer (rising PSA while testosterone levels remain <50 ng/mL).

Results: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated.

Conclusions: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.

Downloads

Download data is not yet available.

Author Biography

Laurence Klotz, Sunnybrook Health Sciences Centre, University of Toronto

Professor, Dept of Surgery

Downloads

Published

2014-11-24

How to Cite

Klotz, L., Nabid, A., Higano, C., Ryan, C., Kebabdjian, marlene, & Chin, J. (2014). Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. Canadian Urological Association Journal, 8(11-12), e789–94. https://doi.org/10.5489/cuaj.2332

Issue

Vol. 8 No. 11-12 (2014): CUAJ November

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.